Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prezalumab - Amgen/AstraZeneca

Next Previous
Drug Profile

Prezalumab - Amgen/AstraZeneca

Alternative Names: AMG-557; B7RP-1 mAb; MEDI-5872

Latest Information Update: 06 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; MedImmune
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action B7-related protein 1 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cutaneous lupus erythematosus; Psoriasis; Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 15 Mar 2021 Viela Bio has been acquired and merged into Horizon Therapeutics plc
  • 08 Nov 2019 Adverse events, efficacy and immunogenicity data from a phase II trial in Sjogren's syndrome presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)
  • 26 Apr 2019 Discontinued - Phase-II for Sjogren's syndrome in France, Sweden, United Kingdom, USA (SC) (AstraZeneca pipeline, April 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top